Clinical trial · Observational
Parotid-sparing IMRT for Nasopharyngeal Cancer
Phase II Study of Parotid Sparing IMRT for Nasopharyngeal Cancer
NCT02149641CI-TRIAL-00014726completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In the treatment of nasopharyngeal cancers, to determine the incidence of high grade (≥G2) subjective xerostomia at 1 year.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Intensity Modulated Radiotherapy With Chemotherapy | — | UNRESOLVED | — |
| Nasopharyngeal Cancers | Malignant Nasopharyngeal Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Intensity modulated radiotherapy with chemotherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Nasopharyngeal cancers
- description
- Intensitiy modulated radiotherapy with chemotherapy
- interventionNames
- Radiation: Intensity modulated radiotherapy with chemotherapy
Primary outcomes (1)
- measure
- the incidence of ≥G2 xerostomia at 1 year using the subjective component LENTSOMA
- timeFrame
- 12 months
Secondary outcomes (4)
- measure
- Acute radiation toxicities
- timeFrame
- 0-3 months
- measure
- Late radiation toxicities
- timeFrame
- 3-24 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 16 Years
Show eligibility criteria text
Inclusion Criteria: * nasopharyngeal cancers Exclusion Criteria: * Patients \<16 years old or with a previous malignancy other than non-melanomatous skin cancer were excluded
References
Publications (0)
Data not yet available
No reference posted for this study.